1
Engels, CC, Charehbili, A, van de Velde, CJH, Bastiaannet, E, Sajet, A, Putter, H, van Vliet, EA, van Vlierberghe, RLP, Smit, VTHBM, Bartlett, JMS, Seynaeve, Caroline, Liefers, GJ, Kuppen, PJK
Veröffentlicht in: Engels , CC , Charehbili , A , van de Velde , CJH , Bastiaannet , E , Sajet , A , Putter , H , van Vliet , EA , van Vlierberghe , RLP , Smit , VTHBM , Bartlett , JMS , Seynaeve , C , Liefers , GJ & Kuppen , PJK 2015 , ' The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis ' , Breast Cancer Research and Treatment , vol. 149 , no. 3 , pp. 587-596 . https://doi.org/10.1007/s10549-015-3269-7;
2015
Veröffentlicht in: Engels , CC , Charehbili , A , van de Velde , CJH , Bastiaannet , E , Sajet , A , Putter , H , van Vliet , EA , van Vlierberghe , RLP , Smit , VTHBM , Bartlett , JMS , Seynaeve , C , Liefers , GJ & Kuppen , PJK 2015 , ' The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis ' , Breast Cancer Research and Treatment , vol. 149 , no. 3 , pp. 587-596 . https://doi.org/10.1007/s10549-015-3269-7;
2015
2
Beije, Nick, Kraan, Jaco, Taal, Walter, van der Holt, Ronnie, Oosterkamp, HM, Walenkamp, AM, Beerepoot, L, Hanse, M, van Linde, ME, Otten, A, Vernhout, René, de Vos, FYF, Gratama, Jan willem, Sleijfer, Stefan, van den Bent, Martin
Veröffentlicht in: Beije , N , Kraan , J , Taal , W , van der Holt , R , Oosterkamp , HM , Walenkamp , AM , Beerepoot , L , Hanse , M , van Linde , ME , Otten , A , Vernhout , R , de Vos , FYF , Gratama , J W , Sleijfer , S & van den Bent , M 2015 , ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ' , British Journal of Cancer , vol. 113 , no. 2 , pp. 226-231 . https://doi.org/10.1038/bjc.2015.191;
2015
Veröffentlicht in: Beije , N , Kraan , J , Taal , W , van der Holt , R , Oosterkamp , HM , Walenkamp , AM , Beerepoot , L , Hanse , M , van Linde , ME , Otten , A , Vernhout , R , de Vos , FYF , Gratama , J W , Sleijfer , S & van den Bent , M 2015 , ' Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial ' , British Journal of Cancer , vol. 113 , no. 2 , pp. 226-231 . https://doi.org/10.1038/bjc.2015.191;
2015
3
Liu, J (Jingjing), Prager - van der Smissen, Wendy, Schmidt, MK (Marjanka), Collee, Margriet, Cornelissen, S, Lamping, Roy, Nieuwlaat, Anja, Foekens, John, Hooning, Maartje, Verhoef, S, van den Ouweland, Ans, Hogervorst, FBL, Martens, John, Hollestelle, Antoinette
Veröffentlicht in: Liu , J , Prager - van der Smissen , W , Schmidt , MK , Collee , M , Cornelissen , S , Lamping , R , Nieuwlaat , A , Foekens , J , Hooning , M , Verhoef , S , van den Ouweland , A , Hogervorst , FBL , Martens , J & Hollestelle , A 2016 , ' Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk ' , Scientific Reports , vol. 6 , 30026 . https://doi.org/10.1038/srep30026;
2016
Veröffentlicht in: Liu , J , Prager - van der Smissen , W , Schmidt , MK , Collee , M , Cornelissen , S , Lamping , R , Nieuwlaat , A , Foekens , J , Hooning , M , Verhoef , S , van den Ouweland , A , Hogervorst , FBL , Martens , J & Hollestelle , A 2016 , ' Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk ' , Scientific Reports , vol. 6 , 30026 . https://doi.org/10.1038/srep30026;
2016
4
Franken, Margreet, Kanters, Tim, Coenen, JL, De Jong, P, Koene, HR, Lugtenburg, Elly, Jager, Agnes, Uyl - de Groot, Carin
Veröffentlicht in: Franken , M , Kanters , T , Coenen , JL , De Jong , P , Koene , HR , Lugtenburg , E , Jager , A & Uyl - de Groot , C 2018 , ' Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands ' , Anti-Cancer Drugs , vol. 29 , no. 8 , pp. 791-801 . https://doi.org/10.1097/CAD.0000000000000648;
2018
Veröffentlicht in: Franken , M , Kanters , T , Coenen , JL , De Jong , P , Koene , HR , Lugtenburg , E , Jager , A & Uyl - de Groot , C 2018 , ' Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands ' , Anti-Cancer Drugs , vol. 29 , no. 8 , pp. 791-801 . https://doi.org/10.1097/CAD.0000000000000648;
2018